Sanara MedTech (SMTI) Q1 2026 Earnings Transcript

Motley Fool Transcribing, The Motley Fool

Tue, June 2, 2026 astatine 11:56 AM CDT 15 min read

Image source: The Motley Fool.

Date

Tuesday, March 24, 2026 astatine 8 a.m. ET

Call participants

• Chief Executive Officer — Seth Yon

• Chief Financial Officer — Elizabeth Taylor

Need a punctuation from a Motley Fool analyst? Email [email protected]

Full Conference Call Transcript

Seth Yon: Thank you, operator, and welcome, everyone, to our archetypal 4th 2026 net league call. This was a beardown 4th for us, which exceeded our expectations. Q1 2026 was the archetypal afloat 4th successful which we were wholly absorption connected the surgical market. and the results bespeak our sharpened focused and enhanced fiscal model. We delivered 19% gross maturation compared to the archetypal 4th of 2025, borderline betterment and broke done to GAAP nett profitability with nett income from continuing operations of $0.4 cardinal oregon $0.04 per diluted share. Our archetypal 4th gross maturation was mostly supported by accrued income of our brushed insubstantial repair products, including CellerateRX and BIASURGE.

Demand for our products is strong, and we're peculiarly pleased with our archetypal 4th results fixed that our archetypal 4th is historically our seasonally slowest income play of the year. The 4th was besides impacted by a 3-day related shutdown successful January, which caused america to suffer 3 days of shipping during this period. Despite these challenges, we closed retired the archetypal 4th with the strongest income period successful institution past successful March, excluding October of 2024, which benefited from astir $1.8 cardinal of BIASURGE income owed to the manufacture disruption caused by Hurricane Helene.

During the extremity of 2025 and continuing into 2026, we began strengthening our income squad to enactment enhanced nett gross maturation and our heightened absorption connected the surgical market. At 4th end, we had grown our income squad to a full of 43 reps. In summation to strengthening our income team, we're besides precise good positioned with a robust surgeon idiosyncratic network, a increasing fig of hospitals wherever our products are contracted oregon approved to beryllium sold, a increasing fig of facilities wherever our products were sold during the 4th and a starring distributor web for our products that continues to expand. Let maine excavation into that a bit.

As of 4th end, our products were contracted oregon approved to beryllium sold successful implicit 4,000 hospitals and ambulatory country centers passim the United States. Our products were sold successful implicit 1,400 facilities passim the United States, up from much than 1,300 successful the archetypal 4th of past year. And we had agreements with much than 450 distributors compared to 400 astatine this clip past year. Also, portion it's not our signifier to disclose specifics related to our progressive surgeon idiosyncratic base, I'm pleased to stock that we saw coagulated maturation successful the fig of surgeon users connected a year-over-year ground successful Q1.